Literature DB >> 22331587

Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells.

Monica Lupu-Meiri1, Elizabeth Geras-Raaka, Ruth Lupu, Hagit Shapira, Judith Sandbank, Liora Segal, Marvin C Gershengorn, Yoram Oron.   

Abstract

High levels of plasminogen activator inhibitor-1 (PAI-1), which is produced by stromal, endothelial, and cancer cells and has multiple complex effects on cancers, correlate with poor cancer prognosis. To more definitively study the role of endogenously produced PAI-1 in human pancreatic adenocarcinoma (PAC) PANC-1 cell line biology, we used anti-PAI-1 shRNA to create stable PAI-1 deficient cells (PD-PANC-1s). PD-PANC-1s exhibited a heterogeneous morphology. While the majority of cells exhibited a cuboidal shape similar to the parental PANC-1 or the vector-infected control cells, numerous large cells with long filopodia and a neuronal-like appearance were observed. Although both Vector-control cells and PD-PANC-1s expressed mRNAs that are characteristic of mesenchymal, neural, and epithelial phenotypes, epithelial marker RNAs were up-regulated (e.g., E-cadherin, 32-fold) whereas mesenchymal marker RNAs were down-regulated (e.g., Thy1, ninefold) in PD-PANC-1s, suggesting mesenchymal-to-epithelial transition. Neural markers exhibited both up- and down-regulation. Immunocytochemistry indicated that epithelial-like PD-PANC-1s expressed E-cadherin and β-catenin in significantly more cells, while neural-like cells exhibited robust expression of organized β-3-tubulin. PAI-1 and E-cadherin were rarely co-expressed in the same cells. Indeed, examination of PAI-1 and E-cadherin mRNAs expression in additional cell lines yielded clear inverse correlation. Indeed, infection of Colo357 PAC cells (that exhibit high expression of E-cadherin) with PAI-1-expressing adenovirus led to a marked decrease in E-cadherin expression and to enhanced migration of cells from clusters. Our results suggest that endogenous PAI-1 suppresses expression of E-cadherin and differentiation in PAC cells in vitro, supporting its negative impact on tumor prognosis.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22331587      PMCID: PMC3469200          DOI: 10.1002/jcp.24068

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  29 in total

1.  Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.

Authors:  R P Czekay; T A Kuemmel; R A Orlando; M G Farquhar
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

2.  Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma.

Authors:  Pia Lindberg; Ake Larsson; Boye Schnack Nielsen
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

3.  Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Authors:  F Jänicke; M Schmitt; H Graeff
Journal:  Semin Thromb Hemost       Date:  1991-07       Impact factor: 4.180

Review 4.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.

Authors:  Jing Yang; Robert A Weinberg
Journal:  Dev Cell       Date:  2008-06       Impact factor: 12.270

5.  Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.

Authors:  L S Gutierrez; A Schulman; T Brito-Robinson; F Noria; V A Ploplis; F J Castellino
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

6.  Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis.

Authors:  Ulrik Lademann; Maria U Rømer; Peter Buhl Jensen; Kenneth F Hofland; Lise Larsen; Ib Jarle Christensen; Nils Brünner
Journal:  Eur J Cancer       Date:  2005-05       Impact factor: 9.162

7.  Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor).

Authors:  Catherine Fen Li; Christopher Kandel; Frank Baliko; Puviindran Nadesan; Nils Brünner; Benjamin A Alman
Journal:  Oncogene       Date:  2005-02-24       Impact factor: 9.867

8.  The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.

Authors:  Birgitte Vrou Offersen; Boye Schnack Nielsen; Gunilla Høyer-Hansen; Fritz Rank; Stephen Hamilton-Dutoit; Jens Overgaard; Peter A Andreasen
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 9.  The plasminogen activator inhibitor "paradox" in cancer.

Authors:  Bernd R Binder; Judit Mihaly
Journal:  Immunol Lett       Date:  2008-05-02       Impact factor: 3.685

Review 10.  The urokinase plasminogen activator system: a target for anti-cancer therapy.

Authors:  Salvatore Ulisse; Enke Baldini; Salvatore Sorrenti; Massimino D'Armiento
Journal:  Curr Cancer Drug Targets       Date:  2009-02       Impact factor: 3.428

View more
  8 in total

1.  Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).

Authors:  Petra Radulović; Božo Krušlin
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

2.  Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.

Authors:  Yohei Hisada; Kenison B Garratt; Anaum Maqsood; Steven P Grover; Tomohiro Kawano; Brian C Cooley; Jonathan Erlich; Florian Moik; Matthew J Flick; Ingrid Pabinger; Nigel Mackman; Cihan Ay
Journal:  Blood Adv       Date:  2021-01-26

3.  Combined Alcohol Exposure and KRAS Mutation in Human Pancreatic Ductal Epithelial Cells Induces Proliferation and Alters Subtype Signatures Determined by Multi-Omics Analysis.

Authors:  Emalie J Clement; Henry C-H Law; Fangfang Qiao; Dragana Noe; Jose G Trevino; Nicholas T Woods
Journal:  Cancers (Basel)       Date:  2022-04-13       Impact factor: 6.639

Review 4.  Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment.

Authors:  Norbaini Binti Abdol Razak; Gabrielle Jones; Mayank Bhandari; Michael C Berndt; Pat Metharom
Journal:  Cancers (Basel)       Date:  2018-10-11       Impact factor: 6.639

5.  Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Wen-Jing Liu; Li Zhou; Zhi-Yong Liang; Wei-Xun Zhou; Lei You; Tai-Ping Zhang; Yu-Pei Zhao
Journal:  Chin Med J (Engl)       Date:  2018-12-20       Impact factor: 2.628

6.  Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8.

Authors:  Hao-Chen Wang; Yung-Lun Lin; Ching-Cheng Hsu; Ying-Jui Chao; Ya-Chin Hou; Tai-Jan Chiu; Po-Hsien Huang; Ming-Jer Tang; Li-Tzong Chen; Yan-Shen Shan
Journal:  Theranostics       Date:  2019-09-23       Impact factor: 11.556

7.  Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.

Authors:  Tamara A Sussman; Hong Li; Brian Hobbs; Pauline Funchain; Keith R McCrae; Alok A Khorana
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 12.469

Review 8.  Oncolytic viral therapy for pancreatic cancer: current research and future directions.

Authors:  Justin W Ady; Jacqueline Heffner; Elizabeth Klein; Yuman Fong
Journal:  Oncolytic Virother       Date:  2014-02-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.